NCT05375903 2026-01-14
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 1 Completed
UroGen Pharma Ltd.
OX2 Therapeutics
UbiVac
Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical Industries, Inc.